Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for BRAF V600-mutant melanoma, drawn from the whole corpus: 13 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Responses to targeted therapy are almost universal but most are not durable, and resistance through MAPK reactivation has no approved answer.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Resistance atlas · Lines of therapy.
Whether a short targeted-therapy induction before immunotherapy helps has not been settled in a phase 3 trial.
BRAF V600K and non-V600 mutations respond less well and have no dedicated drugs.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 26 changes by month →When this page itself was last checked or edited.
12-month EFS 83.
2-year OS 71.
A milestone in how this cancer is treated.
With atezolizumab and vemurafenib in BRAF V600 melanoma
Atezolizumab added to vemurafenib and cobimetinib prolonged investigator-assessed progression-free survival in BRAF V600-mutant melanoma, without an overall survival benefit; approved in July 2020.